Table 1.
Clinicopathological and molecular characteristics of 16 patients harboring primary EGFR T790M mutation
| No | Sex | Age | Smoking history | Histology | AD subtype | Diff | pTNM | EGFR mutation type | EGFR copy number | Other driver mutation | Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 53 | Never | AD | Acinar | Moderate | Ia | Del E746-A750, T790M | Amplification | – | – |
| 2 | F | 66 | Never | AD | MP | Moderate | IV | L858R, T790M | – | – | Gefitinib |
| 3 | F | 62 | Never | AD | Acinar | Moderate | Ib | L858R, T790M | – | – | – |
| 4 | F | 66 | Never | AD | P | Moderate | IIb | Del E746-A750, T790M | – | – | Erlotinib |
| 5 | F | 64 | Never | AD | Acinar | Moderate | IIa | L858R, T790M | – | – | – |
| 6 | M | 45 | Never | AS | – | Poor | Ib | L858R, T790M | High polysomy | – | – |
| 7 | M | 62 | Smoker | AD | Acinar | Moderate | IIIb | L858R, T790M | Amplification | – | Gemcitabine + cisplatin |
| 8 | F | 62 | Never | AS | – | Poor | IIIa | Del l747-T751, T790M | High polysomy | – | Gemcitabine + cisplatin |
| 9 | F | 65 | Never | AD | Acinar | Moderate | Ib | L858R, T790M | – | – | – |
| 10 | F | 66 | Never | AD | Solid | Poor | IIIa | G719S, T790M | High polysomy | PIK3CA E542K | Gemcitabine + cisplatin |
| 11 | F | 54 | Never | AD | Acinar | Moderate | IIIa | L858R, T790M | High polysomy | – | Paclitaxel + cisplatin |
| 12 | F | 57 | Never | AD | MP | Moderate | Ia | Del L747-T751, T790M | – | – | – |
| 13 | M | 57 | Never | AD | P | Moderate | Ia | Del l747-T751, T790M | – | – | – |
| 14 | F | 58 | Never | AD | P | Moderate | Ia | L858R, T790M | – | – | – |
| 15 | F | 58 | Never | AD | AIS | Moderate | Ia | L858R, T790M | – | – | – |
| 16 | F | 53 | Never | AD | P | Moderate | IIIa | L858R, T790M | – | – | Gemcitabine + cisplatin |
Abbreviations: AD, adenocarcinoma; AIS, adenocarcinoma in situ; AS, adenosquamous carcinoma; Diff, differentiation; EGFR, epidermal growth factor receptor; F, female; M, male; MP, micropapillary predominant; P, papillary predominant; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha; pTNM, pathological TNM stage.